Hamilton D W, Heaven B, Thomson R G, Wilson J A, Exley C
Institute of Health and Society, Newcastle University, Newcastle upon Tyne, UK.
Head and Neck Surgery, Freeman Hospital, Newcastle upon Tyne, UK.
BMJ Open. 2016 Jul 21;6(7):e012559. doi: 10.1136/bmjopen-2016-012559.
To critically examine the process of multidisciplinary team (MDT) decision-making with a particular focus on patient involvement.
Ethnographic study using direct non-participant observation of 35 MDT meetings and 37 MDT clinics, informal interviews and formal, semistructured interviews with 20 patients and 9 MDT staff members.
Three head and neck cancer centres in the north of England.
Patients with a diagnosis of new or recurrent head and neck cancer and staff members who attend the head and neck cancer MDT.
Individual members of the MDT often have a clear view of which treatment they consider to be 'best' in any clinical situation. When disagreement occurs, the MDT has to manage how it presents this difference of opinion to the patient. First, this is because the MDT members recognise that the clinician selected to present the treatment choice to the patient may 'frame' their description of the treatment options to fit their own view of best. Second, many MDT members feel that any disagreement and difference of opinion in the MDT meeting should be concealed from the patient. This leads to much of the work of decision-making occurring in the MDT meeting, thus excluding the patient. MDT members seek to counteract this by introducing increasing amounts of information about the patient into the MDT meeting, thus creating an 'evidential patient'. Often, only highly selected or very limited information of this type can be available or known and it can easily be selectively reported in order to steer the discussion in a particular direction.
The process of MDT decision-making presents significant barriers to effective patient involvement. If patients are to be effectively involved in cancer decision-making, the process of MDT decision-making needs substantial review.
批判性地审视多学科团队(MDT)的决策过程,尤其关注患者的参与情况。
人种志研究,采用直接非参与式观察35次MDT会议和37次MDT门诊,对20名患者和9名MDT工作人员进行非正式访谈和正式的半结构化访谈。
英格兰北部的三个头颈癌中心。
被诊断为新发或复发性头颈癌的患者以及参加头颈癌MDT的工作人员。
MDT的个别成员通常对在任何临床情况下他们认为“最佳”的治疗方法有清晰的看法。当出现分歧时,MDT必须处理如何向患者呈现这种意见分歧。首先,这是因为MDT成员认识到被选中向患者介绍治疗选择的临床医生可能会“构建”他们对治疗方案的描述,以符合自己认为的最佳方案。其次,许多MDT成员认为MDT会议中的任何分歧和意见差异都应向患者隐瞒。这导致决策的许多工作在MDT会议中进行,从而将患者排除在外。MDT成员试图通过在MDT会议中引入越来越多关于患者的信息来抵消这一点,从而创建一个“有证据的患者”。通常,只有经过高度筛选或非常有限的此类信息可用或已知,并且它很容易被有选择地报告,以便将讨论引向特定方向。
MDT决策过程对患者的有效参与构成了重大障碍。如果患者要有效地参与癌症决策,MDT决策过程需要进行实质性审查。